Athanassios Vozikis

ORCID: 0000-0002-8342-3839
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Global Health Care Issues
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy
  • Healthcare Quality and Management
  • Employment and Welfare Studies
  • Health disparities and outcomes
  • Medical Malpractice and Liability Issues
  • Healthcare Policy and Management
  • Healthcare Systems and Reforms
  • Pharmacogenetics and Drug Metabolism
  • BRCA gene mutations in cancer
  • Patient Satisfaction in Healthcare
  • Patient Safety and Medication Errors
  • Global Public Health Policies and Epidemiology
  • Customer Service Quality and Loyalty
  • Health Literacy and Information Accessibility
  • Artificial Intelligence in Healthcare and Education
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Genetics, Bioinformatics, and Biomedical Research
  • Health and Wellbeing Research
  • Lung Cancer Treatments and Mutations
  • Nutrition, Genetics, and Disease
  • Lipoproteins and Cardiovascular Health
  • Biotechnology and Related Fields
  • Primary Care and Health Outcomes

University of Piraeus
2015-2024

University of Patras
2014

Patient satisfaction is an important measure of healthcare quality as it offers information on the provider's success at meeting clients' expectations and a key determinant patients' perspective behavioral intention. The aim this paper first to assess degree patient satisfaction, second, study relationship between system set socio-economic provision indicators. This empirical analysis covers 31 countries for years 2007, 2008, 2009 2012. dependent variable, index, defined their country's...

10.1186/s12913-016-1327-4 article EN cc-by BMC Health Services Research 2016-03-15

Pharmacogenomics (PGx) holds promise to revolutionize modern healthcare. Although there are several prospective clinical studies in oncology and cardiology, demonstrating a beneficial effect of PGx-guided treatment reducing adverse drug reactions, very few such psychiatry, none which spans across all main psychiatric indications, namely schizophrenia, major depressive disorder bipolar disorder. In this study we aim investigate the effectiveness (occurrence hospitalisations re-admissions,...

10.1016/j.ebiom.2024.105009 article EN cc-by-nc-nd EBioMedicine 2024-02-16

Background: Understanding the factors that influence eHealth in a country is particularly important for health policy decision makers and care market, as it provides critical information to develop targeted tailored interventions relevant patient–consumer segments, further suggests appropriate strategies training illiterate part of population.

10.2196/ijmr.4749 article EN cc-by Interactive Journal of Medical Research 2016-05-25

Health literacy is widely considered as a key determinant of health and priority in the public policy agenda. Low has been associated with poorer states, broader inequalities higher systems' costs. In present study we bring into focus functional among university students Greece, researching assessing mainly their ability to apply basic knowledge context. The was carried out during period 15–30 April 2013, random sample 1,526 14 Higher Tertiary Public universities Technological Educational...

10.1186/2049-3258-72-15 article EN cc-by Archives of Public Health 2014-05-23

Cardiovascular diseases and especially Acute Coronary Syndrome (ACS) constitute a major health issue impacting millions of patients worldwide. Being leading cause death hospital admissions in many European countries including Spain, it accounts for enormous amounts healthcare expenditures its management. Clopidogrel is one the oldest antiplatelet medications used as standard care ACS.In this study, we performed an economic evaluation study to estimate whether genome-guided clopidogrel...

10.1186/s40246-023-00495-3 article EN cc-by Human Genomics 2023-06-07

Background & methods: Economic evaluation in genomic medicine is an emerging discipline to assess the cost–effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model whether pharmacogenomic (PGx)-guided warfarin treatment elderly ischemic stroke patients with atrial fibrillation Croatia cost effective compared non-PGx therapy. The time horizon was set at 1 year. Results: Our primary analysis indicates that 97.07% (95% CI: 94.08–99.34%) belonging PGx-guided group...

10.2217/pgs.14.167 article EN Pharmacogenomics 2015-01-01

Aim: In the postgenomic era, in many European countries, very little is known regarding level of awareness healthcare professionals with respect to pharmacogenomics and personalized medicine. Methods: Here, we report findings an in-depth study, involving 86 pharmacists 208 physicians, assess their Results: Our indicate that approximately 60% consider knowledge medicine be low, while over half physicians intimate they would unable explain results pharmacogenomic tests customers or patients,...

10.2217/pme.13.92 article EN Personalized Medicine 2014-01-01

Background: The incorporation of genomic testing into clinical practice constitutes an opportunity to improve patients' lives, as it makes possible the implementation innovative, individualized interventions that maximize efficacy and/or minimize risk adverse drug reactions. In order ensure equal access for all patients, costs associated with these tests should be reimbursed by their respective national healthcare systems. Given funding public health sector is decreasing in real terms,...

10.3389/fphar.2019.00830 article EN cc-by Frontiers in Pharmacology 2019-08-02

Autoimmune diseases (ADs) are chronic disorders characterized by the loss of self-tolerance, and although being heterogeneous, they share common pathogenic mechanisms. Self-antigens inflammation markers established diagnostic tools; however, metabolic imbalances that underlie ADs poorly described. The study aimed to employ metabolomics for detection disease-related changes in autoimmune could have predictive value. Quantitative analysis 28 urine organic acids was performed using Gas...

10.3390/metabo10120502 article EN cc-by Metabolites 2020-12-08

The pace of discoveries and advances in genomic research is not reflected the their translation incorporation into day-to-day clinical medicine to individualize healthcare decision-making processes. One main obstacles poor understanding policies key stakeholders involved these processes.We used computerized version PolicyMaker political mapping tool collect organize important information about pharmacogenomics policy environment, serving as a database for assessments policy's content, major...

10.1159/000365896 article EN Public Health Genomics 2014-01-01

<h3>Background</h3> We investigated the impact of cigarette price differences across European Union (EU) on cross-border tobacco purchasing because cheaper among current smokers. <h3>Methods</h3> Individual-level tobacco-related data (including behavior) were from Special Eurobarometer 385 (V.77.1), a cross-sectional survey persons aged ≥15 years 27 EU Member States during 2012. Country-specific weighted average prices (WAP) per 1000 cigarettes (as 1 July 2012) obtained Commission, and...

10.1136/tobaccocontrol-2014-052015 article EN Tobacco Control 2015-02-06

Abstract Pharmacogenomics holds promise of personalized treatment for patients suffering from many common diseases, particularly those with multiple modalities. Owing to recent advances in the deciphering human genome sequence, high throughput genotyping technology has led reduction overall costs genetic testing and allowed inclusion genotype-related dosing recommendations into drug package inserts, hence enabling integration pharmacogenomics clinical practice. Although gradually assumes an...

10.1515/dmdi.2011.028 article EN Drug metabolism and drug interactions 2011-10-22

The Genomic Medicine Alliance is a global academic research network that aims to establish and strengthen collaborative ties between the various genomic medicine stakeholders. Its focus lies on translation of scientific findings into clinical practice. It brings together experts from disciplines including genome informatics, pharmacogenomics, public health genomics, ethics in genomics economics, it supervised by 14-member International Scientific Advisory Committee comprising internationally...

10.2217/pme.14.59 article EN Personalized Medicine 2014-09-01

Medical tourism is a rapidly growing sector, and could become major driver of in Greece. This research examines the status quo potential medical on island Crete, A cross-sectional study was conducted from January 2021 to February 2022, with administration questionnaires. The involved participation 97 hotel managers four- five-star hotels, 515 doctors representing various specialties, 890 tourists. Hotel overwhelmingly (90+%) believe that can significantly contribute domestic economy, as well...

10.3390/su152416822 article EN Sustainability 2023-12-14

10.1016/j.ijinfomgt.2008.04.012 article EN International Journal of Information Management 2009-01-10

<h3>Objectives</h3> Greece is in an economic crisis compounded by the costs caused smoking. The present investigation estimates and public health benefits ensuing from recent cigarette excise tax increase 2011 projects potential additional €2.00 per pack increase. <h3>Methods</h3> effects of were calculated on outcome measures: total price pack, including specific excise, ad valorem tax, value-added consumption; revenue; capita consumption cigarettes. Additionally, smoking-attributable...

10.1136/tobaccocontrol-2012-050857 article EN Tobacco Control 2013-03-06

Introduction: Clopidogrel, which is activated by the CYP2C19 enzyme, among drugs for all major regulatory agencies recommend genetic testing to be performed identify a patient's genotype in order determine optimal antiplatelet therapeutic scheme. The CYP2C19*2 and CYP2C19*3 variants are loss-of-function alleles, leading abolished function thus have risk of thrombotic events carriers these alleles on standard dosages, while CYP2C19*17 allele results hyperactivity. Aims: Here, we report our...

10.2217/pgs-2016-0052 article EN Pharmacogenomics 2016-10-21

The dawn of artificial intelligence (AI) as a platform for improved health care provides unparalleled opportunity to enhance patient and clinical team performance, minimize costs, reduce the effects community. It broad description legal legislative context AI tools intended implementation care; highlights need equality, accessibility, human rights goal work; identifies important factors further advancement. framework describes obstacles, drawbacks, best practices development, adoption,...

10.12681/hapscpbs.24958 article EN HAPSc Policy Briefs Series 2020-06-30
Coming Soon ...